On Monday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) marked $85.50 per share versus a previous $81.34 closing price. With having a 5.11% gain, an insight into the fundamental values of Arena Pharmaceuticals, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. ARNA showed a rise of 88.24% within its YTD performance, with highs and lows between $32.95 – $86.58 during the period of 52 weeks, compared to the simple moving average of 46.71% in the period of the last 200 days.
JP Morgan equity researchers changed the status of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares to a “Overweight” rating in the report published on September 14th, 2020. Other analysts, including H.C. Wainwright, also published their reports on ARNA shares. H.C. Wainwright repeated the rating from the previous report, marking ARNA under “Buy” rating, in the report published on June 29th, 2020. Additionally, ARNA shares got another “Buy” rating from Jefferies, setting a target price of $62 on the company’s shares, according to the report published in May 18th, 2020. On March 31st, 2020, Guggenheim Initiated an Buy rating and increased its price target to $95. On the other hand, BofA/Merrill Upgrade the “Buy” rating for ARNA shares, as published in the report on March 26th, 2020. JP Morgan seems to be going bullish on the price of ARNA shares, based on the price prediction for ARNA, indicating that the shares will jump to $58, giving the shares “Overweight” rating based on their report from January 31st, 2020. Another “Neutral” rating came from BofA/Merrill, providing a prediction for $58 price target according to the report published in November 13th, 2019.
[bold-text]Arena Pharmaceuticals, Inc. (ARNA) Analysis[/bold-text]
The present dividend yield for ARNA owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording , hinting the company’s progress in the upcoming progress.
In order to gain a clear insight on the performance of Arena Pharmaceuticals, Inc. (ARNA) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -31.10% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 28.80 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.
Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while ARNA is currently recording an average of 569.75K in volumes. The volatility of the stock on monthly basis is set at 3.79%, while the weekly volatility levels are marked at 4.16%with 10.27% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $93.15, indicating growth from the present price of $85.50, which can represent yet another valuable research and analysis points that can help you decide whether to invest in ARNA or pass.
[bold-text]What to Look for When Analyzing Arena Pharmaceuticals, Inc. Shares?[/bold-text]
Arena Pharmaceuticals, Inc. (ARNA) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare ARNA shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Arena Pharmaceuticals, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -6.83 is supported by the yearly EPS growth of -199.00%.
Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 0.10%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 93.90% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.
[bold-text]Are Institutional Investors Increasing Stakes in ARNA Shares?[/bold-text]
It appears that more than several institutional investors and hedge funds decided to increase stakes in ARNA in the recent period. That is how The Vanguard Group, Inc. now has an increase position in ARNA by 10.19% in the first quarter, owning 5.04 million shares of ARNA stocks, with the value of $377.15 million after the purchase of an additional 466,433 shares during the last quarter. In the meanwhile, BlackRock Fund Advisors also increased their stake in ARNA shares changed 14.61% in the first quarter, which means that the company now owns 4.06 million shares of company, all valued at $303.92 million after the acquisition of additional 518,140 shares during the last quarter.
SSgA Funds Management, Inc. acquired a new position in Arena Pharmaceuticals, Inc. during the first quarter, with the value of $155.26 million, and Lord, Abbett & Co. LLC increased their stake in the company’s shares by 69.63% in the first quarter, now owning 592,384 shares valued at $107.93 million after the acquisition of the additional 1.44 million shares during the last quarter. In the end, Alkeon Capital Management LLC increased their position by 175.33% during the first quarter, now owning 1.41 million ARNA shares, now holding the value of $105.5 million in ARNA with the purchase of the additional 814,076 shares during the period of the last quarter. At the present, 93.90% of ARNA shares are in the ownership of institutional investors.